Is Neuroscience Back In Vogue? Sanofi Preps For R&D Dominance
Executive Summary
Sanofi is building up a neuroscience portfolio from its legacy multiple sclerosis and rare disease foundations by pursuing early-stage research in neurodegeneration, neuro-inflammation and rare brain diseases. Neuroscience professor and former Pfizer drug development leader, Rita Balice-Gordon, will use her academic assessment lens to find the best science and utilize patient groups to bridge the gap between research and neuro disease therapeutics making it all the way to market.
You may also be interested in...
Sanofi Expands MS Portfolio With BTK Inhibitor From Principia
The French pharma adds the Phase I candidate to its Lemtrada follow-on for multiple sclerosis development, while Principia will use $40m in upfront cash to advance its orphan disease strategy.
VC View: Deal-Making During A Pandemic And 2021 Expectations
In the latest instalment of VC Playbook, In Vivo gets to know Arix Bioscience, a relatively young venture capital firm that went public in 2016. Arix has “has many similarities yet some key differences from a typical venture capital firm,” says the management team.
Snapshot: August Highlights
A selection of articles you might have missed from August 2020, including exclusive interviews with industry leaders and a review of financing trends.
Need a specific report? 1000+ reports available
Buy Reports